Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
N. Sattar, D.W. McCarey, H. Capell, I.B. McInnes.
Explaining how “highgrade” sytemic inflammation accelerates vascular risk in rheumatoid arthritis.
Circulation, 108 (2003), pp. 2957-2963
[2.]
M. Boers, B. Dijkmans, S.E. Gabriel, H. Maradit-Kremers, J. O’Dell, T. Pincus.
Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity.
Arthritis Rheum, 50 (2004), pp. 1734-1739
[3.]
I.D. Del Rincón, K. Williams, M.P. Stern, G.L. Freeman, A. Escalante.
High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors.
Arthritis Rheum, 44 (2001), pp. 2737-2745
[4.]
N. Goodson.
Coronary artery disease and rheumatoid arthritis.
Curr Opin Rheumatol, 14 (2002), pp. 115-120
[5.]
H.K. Choi, M.A. Hernan, J.D. Seeger, J.M. Robins, F. Wolfe.
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.
Lancet, 359 (2002), pp. 1173-1177
[6.]
G.D. Kitas, N. Erb.
Tackling ischaemic heart disease in rheumatoid arthritis.
Rheumatology, 42 (2003), pp. 607-613
[7.]
P.J. Nicola, H. Maradit-Kremers, V.L. Roger, S.J. Jacobsen, C.S. Crowson, K.V. Ballman, et al.
The risk of congestive heart failure in a rheumatoid arthritis: a population-based cohort study over 46 years.
Arthritis Rheum, 52 (2005), pp. 412-420
[8.]
C. Popa, P.M. Welsing, M. Veerkamp, P.L.C.M. Van Riel.
Cardiovascular risk factors in RA and their modulation during TNF-α blokade.
Int J Adv Rheumatol, 3 (2005), pp. 70-76
[9.]
C. Turesson, A. Jarenros, L. Jacobsson.
Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study.
Ann Rheum Dis, 63 (2004), pp. 952-955
[10.]
N.J. Goodson, D.P.M. Symmons, D.G.I. Scott, D. Bunn, M. Lunt, A.J. Silman.
Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis. A ten-year followup study of a primary care-based inception cohort.
Arthritis Rheum, 52 (2005), pp. 2293-2299
[11.]
L.T.H. Jacobsson, C. Turesson, R.L. Hanson, S. Pillemer, M.L. Sievers, D.J. Pettitt, et al.
Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima indians.
Arthritis Rheum, 44 (2001), pp. 1170-1176
[12.]
H. Maradit-Kremers, C.S. Crowson, P.J. Nicola, K.V. Ballman, V.L. Roger, S.J. Jacobsen, et al.
Increased underrecognized coronary heart disease and sudden deaths in a rheumatoid arthritis: a population-based cohort study.
Arthritis Rheum, 52 (2005), pp. 402-411
[13.]
M.M. Nielen, D. Van Schaardenburg, H.W. Reesink, R.J. Van der Stadt, I.E. Van der Horst-Bruinsma, M.H. De Koning, et al.
Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors.
Arthritis Rheum, 50 (2004), pp. 380-386
[14.]
I. Del Rincón, R.W. Haas, S. Pogosian, A. Escalante.
Lower lim arterial incompressibility and obtruction in rheumatoid arthritis.
Ann Rheum Dis, 64 (2005), pp. 425-432
[15.]
K.J. Warrington, P.D. Kent, R.L. Frye, J.F. Lymp, S.L. Kopecky, J.J. Goronzy, et al.
Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study.
Arthritis Research Therapy, 7 (2005), pp. 984-991
[16.]
N.J. Goodson, J. Marks, M. Lunt, D.P. Symmons.
Cardiovascular admissions and mortality in a inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s.
Ann Rheum Dis, 64 (2005), pp. 1595-1601
[17.]
S. Van Doornum, B. King, C. Brand, V. Sundarajan.
Mortality rates following a first acute cardiovascular event. A comparison between rheumatoid arthritis patients and the general population.
Arthritis Rheum, 52 (2005), pp. S702
[18.]
L. Colglazier, F. Wolfe, K. Michaud.
Rheumatoid arthritis patients are less likely to be treated with prophylactic aspirin despite an increased risk of myocardial infarction.
Arthritis Rheum, 52 (2005), pp. S704
[19.]
H. Maradit-Kremers, P.J. Nicola, C.S. Crowson, K.V. Ballman, S.E. Gabriel.
Cardiovascular death in rheumatoid arthritis. A population-based study.
Arthritis Rheum, 52 (2005), pp. 722-732
[20.]
S.P. Kulkarni, K.P. Alexander, B. Lytle, G. Heiss, E.D. Peterson.
Long-term adherence with cardiovascular drug regimens.
Am Heart J, 151 (2006), pp. 185-191
[21.]
D.W. McCarey, I.B. McInnes, R. Madhok, R. Hampson, O. Scherbakov, I. Ford, et al.
Trial of atorvastatin in rheumatoid arthritis (TARA): double- blind, randomised placebo-controlled trial.
Lancet, 363 (2004), pp. 2015-2021
[22.]
E. Krishnan, V.B. Lingala, G. Singh.
Declines in mortality from acute myocardial infarction in successive incidende and birth cohorts of patients with rheumatoid arthritis.
Circulation, 110 (2004), pp. 1774-1779
[23.]
A.J. Silman.
Has the incidence of rheumatoid arthritis declined in the United Kingdom?.
Br J Rheumatol, 27 (1988), pp. 77-79
[24.]
N.J. Goodson, N.J. Wiles, M. Lunt, E. Barrett, A.J. Silman, D.P. Symmons.
Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients.
Arthritis Rheum, 46 (2002), pp. 2010-2019
[25.]
E. Krishnan, J.F. Fries.
Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients.
Am J Med, 115 (2003), pp. 371-376
El presente trabajo está financiado por una Beca de Ayuda a la Investigación de la Fundación de Investigación Médica Mutua Madrileña 2005.
Copyright © 2006. Elsevier España S.L. Barcelona
